Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Kalytera Announces Positive Phase 2 CBD Test Results

Stockhouse Editorial
0 Comments| December 20, 2018

Kalytera Therapeutics Inc. (TSX: V.KALY, OTCQB: KALTF, Forum) reported positive interim data on Thursday from its ongoing Phase 2 clinical study evaluating cannabidiol (CBD) for the prevention of acute graft versus host disease following bone marrow transplant.

More information can be found here.

The Company also made news this week when it entered into agreements to sell an aggregate 11,532,000 of its common shares and 11,532,000 common share purchase warrants for aggregate gross proceeds of $605,430 (CAD).

FULL DISCLOSURE: Kalytera Therapeutics Inc. is a client of Stockhouse Publishing.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.